Sermorelin (GHRH 1-29) is a synthetic analogue of growth hormone-releasing hormone investigated for pituitary GH secretion, somatotropic axis function, and age-related GH deficiency research.
| Molecular Weight | 3358.0 g/mol |
| Purity | >98% |
| Form | Lyophilized powder |
| Storage | -20°C |
Science-backed research overview for this compound
Sermorelin is a synthetic peptide consisting of the first 29 amino acids of the natural Growth Hormone-Releasing Hormone (GHRH). It is the shortest functional fragment of GHRH that still possesses the full biological activity of the parent molecule.
Sermorelin works by binding to the GHRH receptors in the pituitary gland, stimulating it to produce and release more Growth Hormone (GH). Unlike direct HGH injections, Sermorelin promotes a more natural, pulsatile release of GH and is subject to the body's natural feedback loops, preventing the "shutdown" of the endocrine system.
Research into Sermorelin is focused on its ability to reverse age-related growth hormone decline. It is studied for its potential to improve sleep quality, increase lean muscle mass, reduce body fat, and enhance bone density. Because it works with the body's natural systems, it is a preferred subject for long-term health and wellness studies.